Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
HSD17B3 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HSD17B3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HSD17B2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HSD17B2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HSD17B1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HSD17B1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HSD11B2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HSD11B2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HSD11B1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HSD11B1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HDAC9 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HDAC9, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HDAC7 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HDAC7, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HDAC5 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HDAC5, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
HDAC4 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for HDAC4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
VK-2735 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
VK-2735 is a Synthetic peptide targeting GIPR x GLP-1R, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
ESR2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ESR2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Depemokimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Depemokimab is a Monoclonal antibody targeting IL-5, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.